Janux Therapeutics, Inc. Common Stock
Symbol: JANX (NASDAQ)
24.10
▼ (-1.41%) -0.345
Company Description:
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Key Stats
- Today's Open: $24.336
- Today's High: $24.336
- Today's Low: $23.816
- Today's Volume: 693
- Yesterday Close: $24.44
- Yesterday High: $24.68
- Yesterday Low: $22.915
- Yesterday Volume: 1.01M
- Last Min Volume: 17
- Last Min High: $24.095
- Last Min Low: $24.095
- Last Min VWAP: $24.095
Company Profile
- Name: Janux Therapeutics, Inc. Common Stock
- Website: https://www.januxrx.com
- Listed Date: 2021-06-11
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001817713
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.47B
- Round Lot: 100
- Outstanding Shares: 60.09M
- Asset Type: CS
RECENT FILINGS FOR JANX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-19 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-17 | SCHEDULE 13G | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 8-K | View |
| 2025-06-04 | 4 | View |
| 2025-05-23 | 3 | View |
| 2025-05-14 | SCHEDULE 13G/A | View |
Latest News on JANX